Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1316-1326

  Ponce, Doris M ^a,b   Zheng, Junting ^a   Gonzales, Anne Marie ^a   Lubin, Marissa ^a   Heller, Glenn ^a   Castro Malaspina, Hugo ^a,b   Giralt, Sergio ^a   Hsu, Katharine ^a,b   Jakubowski, Ann A ^a,b   Jenq, Robert R ^a,b   Koehne, Guenther ^a,b   Papadopoulos, Esperanza B ^a,b   Perales, Miguel A ^a,b   van den Brink, Marcel R ^a,b   Young, James W ^a,b   Boulad, Farid ^a,b   Kernan, Nancy A ^a   Kobos, Rachel ^a   Prockop, Susan ^a   Scaradavou, Andromachi ^a   Small, Trudy ^a,b   O'Reilly, Richard J ^a,b   Barker, Juliet N ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cord blood transplantation

Indexed keywords

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROGRESSION FREE SURVIVAL; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TISSUE DONORS; YOUNG ADULT;

EID: 79954631207     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.006     Document Type: Article

References (32)

1. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
2. Eapen M., Rubinstein P., Zhang M.J., et al. Comparison of outcomes after transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia. Lancet 2007, 369:1947-1954.
3. Kurtzberg J., Prasad V.K., Carter S.L., et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008, 112:4318-4327.
4. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009, 147:262-274.
5. Barker J.N., Byam C.E., Kernan N.A., et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 2010, 16:1541-1548.
6. Gluckman E. Ten years of cord blood transplantation: from bench to bedside. Br J Haematol 2009, 147:192-199.
7. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276-2285.
8. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
9. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
10. Barker J.N., Abboud M., Rice R.D., et al. A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant 2009, 15:1596-1602.
11. Scaradavou A., Smith K.M., Hawke R., et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010, 16:500-508.
12. Jakubowksi A.A., Small T.N., Young J.W., et al. T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007, 110:4552-4559.
13. Bacher U., Haferlach C., Schnittger S., et al. Interactive diagnostics in the indication to allogeneic SCT in AML. Bone Marrow Transplant 2009, 43:745-756.
14. Balduzzi A., Valsecchi M.G., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005, 366:635-642.
15. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
16. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
17. Copelan E., Casper J.T., Carter S.L., et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007, 13:1469-1476.
18. Chevallier P., Hebia-Fellah I., Planche L., et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2009, 45:1204-1211.
19. Barker J.N., Weisdorf D.J., DeFor T.E., Blazar B.R., Miller J.S., Wagner J.E. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003, 102:1915-1919.
20. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
21. Brunstein C., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after non-myeloablative conditioning: impact on transplant outcomes in 110 adults with hematological disease. Blood 2007, 110:3064-3070.
22. Majhail N.S., Mothukuri J.M., Brunstein C.G., Weisdorf D.J. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009, 15:564-573.
23. Rodrigues C.A., Sanz G., Brunstein C.G., et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009, 27:256-263.
24. Barker J.N., Scaradavou A., Stevens C.E. Combined effect of total nucleated cell dose and HLA-match on transplant outcome in 1061 cord blood recipients with hematological malignancies. Blood 2010, 115:1843-1849.
25. Malard F., Szydlo R.M., Brissot E., et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:28-34.
26. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005, 78:486-500.
27. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
28. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
29. Eldjerou L.K., Chaudhury S., Baisre-de Leon A., et al. An in vivo model of double unit cord blood transplantation that correlates with clinical engraftment. Blood 2010, 116:3999-4006.
30. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998, 91:1083-1090.
31. Small T.N., Young J.W., Castro-Malaspina H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:235-244.
32. Castro-Malaspina H., Jakubowski A.A., Papadopoulos E.B., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458-468.